Former Executive of Crypto Lending Firm Cred Admits to Wire Fraud Charges
According to Cointelegraph, former CEO Daniel Schatt and CFO Joseph Podulka of the bankrupt crypto lending platform Cred have admitted to charges of wire fraud in a federal court in California. As per the plea agreement, both acknowledged inducing customers to lend funds through selective information disclosure, resulting in user losses ranging from $65 million to $150 million. The judge is set to sentence on August 26, with the prosecution recommending prison terms of 72 months and 62 months, respectively. After Bitcoin plummeted 40% in March 2020, Cred was on the brink of bankruptcy due to its inability to meet margin requirements, yet executives continued to conceal risks from new customers. Investigations revealed that the platform actually relied on MoKredit's unsecured microloan business, contrary to its claimed "fully collateralized lending" model. When Cred went bankrupt in November 2020, customer losses exceeded $150 million, but some assets are now valued at $783 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
